RAP1A and neoplasm: In vivo, tumor-derived chemoattractants promote the recruitment and infiltration of myeloid cells to the tumor microenvironment by increasing PI3Kγ-Rap1a-integrin α4β1-dependent adhesion to the tumor endothelium.